Anti-L1-CAM antibodies and uses thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsNai-Kong V. Cheung, Hong Xu, Maya Suzuki-Nishijima, Brandon Nemieboka, Jason Lewis
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of L1-CAM protein. The antibodies of the present technology are useful in methods for detecting and treating a L1-CAM-positive cancer in a subject in need thereof.
Claims19
An anti-L1-CAM antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein:
- (a) the VH comprises a VH-CDR1 sequence of GYTFTSYWMQ (SEQ ID NO:
- 53), a VH-CDR2 sequence of EINPSNGRTNYNEMFKS (SEQ ID NO:
- 54), and a VH-CDR3 sequence of YDGYYAMDY (SEQ ID NO:
- 55);
- and
- (b) the VL comprises a VL-CDR1 sequence of KSSQSLLYSSNQKNYLA (SEQ ID NO:
- 56), a VL-CDR2 sequence of WASTRES (SEQ ID NO:
- 57), and a VL-CDR3 sequence of QQYHSYPFT (SEQ ID NO:
- 58),
- optionally wherein the antibody or antigen binding fragment is conjugated to an agent selected from the group consisting of an isotope, a dye, a chromagen, a contrast agent, a drug, a toxin, a cytokine, an enzyme, an enzyme inhibitor, a hormone, a hormone antagonist, a growth factor, a radionuclide, a metal, a liposome, a nanoparticle, RNA, DNA and any combination thereof.
An anti-L1-CAM antibody comprising a heavy chain (HC) amino acid sequence and a light chain (LC) amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 9 and SEQ ID NO:
- 13 (huE71 H1/L1);
- SEQ ID NO:
- 9 and SEQ ID NO:
- 14 (huE71 H1/L2);
- SEQ ID NO:
- 10 and SEQ ID NO:
- 13 (huE71 H2/L1);
- SEQ ID NO:
- 10 and SEQ ID NO:
- 14 (huE71 H2/L2);
- SEQ ID NO:
- 17 and SEQ ID NO:
- 21 (huE72 H1/L1);
- SEQ ID NO:
- 17 and SEQ ID NO:
- 22 (huE72 H1/L2);
- SEQ ID NO:
- 18 and SEQ ID NO:
- 21 (huE72 H2/L1);
- SEQ ID NO:
- 18 and SEQ ID NO:
- 22 (huE72 H2/L2);
- SEQ ID NO:
- 26 and SEQ ID NO:
- 25 (chE71IgG1);
- SEQ ID NO:
- 30 and SEQ ID NO:
- 29 (chE72 IgG1);
- SEQ ID NO:
- 42 and SEQ ID NO:
- 41 (chE71IgG4);
- SEQ ID NO:
- 46 and SEQ ID NO:
- 45 (huE71IgG4);
- SEQ ID NO:
- 49 and SEQ ID NO:
- 50 (huE71 BsAb);
- and
- SEQ ID NO:
- 51 and SEQ ID NO:
- 52 (huE72 BsAb),
- optionally wherein the antibody is conjugated to an agent selected from the group consisting of an isotope, a dye, a chromagen, a contrast agent, a drug, a toxin, a cytokine, an enzyme, an enzyme inhibitor, a hormone, a hormone antagonist, a growth factor, a radionuclide, a metal, a liposome, a nanoparticle, RNA, DNA and any combination thereof.
An anti-L1-CAM antibody or antigen binding fragment thereof comprising the heavy chain immunoglobulin variable domain (VH) amino acid sequence and the light chain immunoglobulin variable domain (VL) amino acid sequence that are present in
- SEQ ID NO:
- 9 and SEQ ID NO:
- 13 (huE71 H1/L1);
- SEQ ID NO:
- 9 and SEQ ID NO:
- 14 (huE71 H1/L2);
- SEQ ID NO:
- 10 and SEQ ID NO:
- 13 (huE71 H2/L1);
- SEQ ID NO:
- 10 and SEQ ID NO:
- 14 (huE71 H2/L2);
- SEQ ID NO:
- 17 and SEQ ID NO:
- 21 (huE72 H1/L1);
- SEQ ID NO:
- 17 and SEQ ID NO:
- 22 (huE72 H1/L2);
- SEQ ID NO:
- 18 and SEQ ID NO:
- 21 (huE72 H2/L1);
- or
- SEQ ID NO:
- 18 and SEQ ID NO:
- 22 (huE72 H2/L2), respectively.
The method of 14, wherein the antibody is administered to the subject separately, sequentially or simultaneously with an additional therapeutic agent.
Dependencies are inferred from the claim text.